Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins

Cancer Gene Therapy volume 11, pages 457–464 (2004)Cite this article

Abstract

DNA vaccines expressing the E6 or E7 oncoproteins of human papilloma virus type 16 (HPV-16) in either their wild-type form or fused to sequences that affect intracellular trafficking were tested for induction of protective immunity against tumor cell challenge in two models based on BALB/c and C57Bl/6 mice. The DNA vaccines to E7 gave uniformly disappointing results, while the DNA vaccine that expressed E6 linked to a viral leader sequence protected BALB/c mice against tumor cell challenge given before or after vaccination. The efficacy of this vaccine could be enhanced by a DNA vector prime/viral vector boost regimen. In contrast, priming of mice with the DNA vaccines to E7 reduced the efficacy of a viral vector expressing the same antigen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186:1396–1402.

    Article  PubMed  Google Scholar 

  2. zur Hausen H . Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55–F78.

    PubMed  Google Scholar 

  3. Munger K, Howley PM . Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213–228.

    Article  CAS  PubMed  Google Scholar 

  4. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1523–1527.

    Article  CAS  PubMed  Google Scholar 

  5. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–26.

    CAS  PubMed  Google Scholar 

  6. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242–2249.

    Article  CAS  PubMed  Google Scholar 

  7. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 2000;270:146–161.

    Article  CAS  PubMed  Google Scholar 

  8. Smahel M, Sima P, Ludvikova V, et al. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology. 2001;281:231–238.

    Article  CAS  PubMed  Google Scholar 

  9. Osen W, Peiler T, Ohlschlager P, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T-cells but lacks transforming activity. Vaccine. 2001;19:4276–4286.

    Article  CAS  PubMed  Google Scholar 

  10. Daemen T, Pries F, Bungener L, et al. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Therapy. 2000;7:1859–1866.

    Article  CAS  PubMed  Google Scholar 

  11. Liu DW, Tsao YP, Hsieh CH, et al. Induction of CD8 T-cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol. 2000;74:9083–9089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA. 1995;92:11671–11675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rodriguez F, Zhang J, Whitton JL . DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol. 1997;71:8497–8503.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Pasquini S, Deng H, Reddy ST, et al. The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector. Gene Therapy. 1999;6:1448–1455.

    Article  CAS  PubMed  Google Scholar 

  15. Wlazlo AP, Giles-Davis W, Clements A, et al. Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV. Hybridoma. 2001;20:257–263.

    Article  CAS  PubMed  Google Scholar 

  16. Deng H, Kowalczyk D, O InSug, et al. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line. Cell Immunol. 2002;215:20–31.

    Article  CAS  PubMed  Google Scholar 

  17. Kowalczyk DW, Wlazlo AP, Shane S, et al. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine. 2001;19:3583–3590.

    Article  CAS  PubMed  Google Scholar 

  18. Fu ZF, Dietzschold B, Schumacher CL, et al. Rabies virus nucleoprotein expressed in and purified from insecT-cells is efficacious as a vaccine. Proc Natl Acad Sci USA. 1991;88:2001–2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Blaszczyk-Thurin M, Ertl IO, Ertl HC . An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scand J Immunol. 2002;56:361–375.

    Article  CAS  PubMed  Google Scholar 

  20. Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, et al. A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods. 2001;253:163–175.

    Article  CAS  PubMed  Google Scholar 

  21. Xiang Z, Ertl HC . Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 1995;2:129–135.

    Article  CAS  PubMed  Google Scholar 

  22. Ramshaw IA, Ramsay AJ . The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000;21:163–165.

    Article  CAS  PubMed  Google Scholar 

  23. Yang ZY, Wyatt LS, Kong WP, et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77:799–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651.

    Article  CAS  PubMed  Google Scholar 

  25. Krieg AM . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–760.

    Article  CAS  PubMed  Google Scholar 

  26. Katz DH, Hamaoka T, Dorf ME, et al. Cell interactions between histoincompatible T and B lymphocytes. IV. Involvement of the immune response (Ir) gene in the control of lymphocyte interactions in responses controlled by the gene. . J Exp Med. 1973;138:734–739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vierboom MP, Feltkamp MC, Neisig A, et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother. 1998;21:399–408.

    Article  CAS  PubMed  Google Scholar 

  28. Schirmbeck R, Bohm W, Ando K, et al. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol. 1995;69:5929–5934.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Xiang ZQ, Pasquini S, Ertl HC . Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol. 1999;162:6716–6723.

    CAS  PubMed  Google Scholar 

  30. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Therapy. 1999;10:2727–2740.

    Article  CAS  Google Scholar 

  31. Reyes-Sandoval A, Ertl HC . DNA vaccines. Curr Mol Med. 2001;1:217–243.

    Article  CAS  PubMed  Google Scholar 

  32. Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T-cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471–6479.

    Article  CAS  PubMed  Google Scholar 

  33. O InSug, Blaszczyk-Thurin M, Shen CT, et al. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Therapy. 2003;10:678–688.

    Article  CAS  PubMed  Google Scholar 

  34. Kotecha MT, Afghan RK, Vasilikopoulou E, et al. Enhanced tumour growth after DNA vaccination against human papillomavirus virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine. 2003;21:2506–2515.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from NCI and NIAID. Dr AP Wlazlo was a recipient of a fellowship from the Cancer Research Foundation of America and from NIH/NIAID. We thank the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health.

Author information

Author notes

  1. Anthony P Wlazlo

    Present address: NIH, NIAID, LID, Respiratory Viruses Section, 50 South Drive MSC-8011, Bethesda, MD, 20892, USA

  2. Hongying Deng

    Present address: Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA

Authors and Affiliations

  1. The Wistar Institute, 3601 Spruce St., Philadelphia, 19104, Pennsylvania, USA

    Anthony P Wlazlo, Hongying Deng, Wynetta Giles-Davis & Hildegund C J Ertl

Authors
  1. Anthony P Wlazlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongying Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wynetta Giles-Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hildegund C J Ertl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hildegund C J Ertl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wlazlo, A., Deng, H., Giles-Davis, W. et al. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther 11, 457–464 (2004). https://doi.org/10.1038/sj.cgt.7700723

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700723

Keywords

This article is cited by

Search

Advanced search

Quick links